The global population will increase to almost ten billion by 2050 while greenhouse gas emissions from agriculture continue to rise. We need to intensify food production while shrinking agriculture’s impact on the environment. Canadian biotechnology is helping farmers produce more food while simultaneously reducing the environmental footprint of agriculture.
Australian biotech, Trimph, has successfully completed a first-in-human trial of its proprietary bone “glue”, TrimphDent, the only bone graft substitute in the world to be applied in liquid form, halving the time of patient recovery, and requiring no specialised preparation or additional surgical expertise.
This breakthrough will allow Trimph to progress towards registering TrimphDent and launching into global markets, which could provide significantly more affordable and accessible oral surgeries to rural and disadvantaged communities across the globe.
An Annapolis firm focused on building medical devices to monitor heart disease has raised $1.5 million to help bring its first product to market.
Vixiar Medical Inc., a spinout of Johns Hopkins, is developing non-invasive devices and systems for monitoring cardiopulmonary diseases. Its seed round included investors from the U.S. Asia and Europe. Local investors include the Abell Foundation and Maryland Technology Development Corp. The company is based on technology licensed from Hopkins and invented by cardiologist Dr. Harry Silber.
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard therapy. Systemic Lupus Erythematosus (SLE) is the most common form of lupus, a chronic, incurable autoimmune disease producing autoantibodies that can attack almost any system in the body. The approval marks the first subcutaneous self-injection treatment option for patients with SLE.
Since 2013, Shire has been stepping up its strategy to become the world’s leading company for people with rare diseases. McKinsey senior partners Martin Dewhurst and Andy West recently talked with Shire’s CEO, Flemming Ørnskov, about the company’s efforts to transform and the importance of staying three steps ahead of the organization you’re leading. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving and how leaders can adapt, Ørnskov discusses his vision for the future and the critical elements of leadership. An edited transcript of their conversation follows.
Elon Musk just tweeted that his Boring Company tunnel project has received “verbal [government] approval” to build a hyperloop connecting New York City, Philadelphia, Baltimore, and Washington, DC.
Master of Professional Studies in Technology Entrepreneurship
The University of Maryland’s Master of Professional Studies (MPS) in Technology Entrepreneurship educates and empowers students to launch and lead innovative startups and corporate ventures. Our unique experiential learning model incorporates online instruction and coaching, global networking opportunities, and funding opportunities with leading investors. This 100% online offering is a 15-month, part-time program for approximately $20,000.
Live Information Session July 24, at 1 p.m., EST
A startup that spun out of research at the University of Maryland School of Medicine was acquired 18 months after forming.
In a deal announced this week, Living Pharma was acquired by Lentigen Technology Inc., a Gaithersburg-based subsidiary of Miltenyi Biotec GmbH. Terms were not disclosed.
VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer.
Richard Mason is head of J&J Innovation for the EMEA region, and identifying and investing in the most promising early-stage drug ideas outside the company is one of his key roles.
This ‘open innovation’ strategy is being pursued by all the big pharma companies – and now it’s simply a matter of who executes best on this approach.
